J3357 Ustekinumab sub cu injection, 1 milligrams
Also known as: ustekinumab, Stelara, IL-12/23 inhibitor
Ustekinumab subcutaneous injection 1 milligram is a monoclonal antibody targeting interleukin-12/23 for psoriasis and inflammatory bowel disease.
In Plain Language
psoriasis treatment injection; skin/gut inflammation medication
Clinical Context
Indicated for moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. Subcutaneous administration with loading dose followed by maintenance dosing. Blocks IL-12 and IL-23 signaling.
RVU Information
CPT J3357 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J3357?
CPT J3357 (Ustekinumab sub cu injection, 1 milligrams) is a J Codes (Drugs) code. Ustekinumab subcutaneous injection 1 milligram is a monoclonal antibody targeting interleukin-12/23 for psoriasis and inflammatory bowel disease.
How is J3357 administered?
CPT J3357 is administered by a healthcare provider, typically via injection or infusion. Indicated for moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. Subcutaneous administration with loading dose followed by maintenance dosing. Blocks IL-12 and IL-23 signaling. It is used by Dermatology, Gastroenterology, Rheumatology.
When is CPT J3357 used?
Indicated for moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. Subcutaneous administration with loading dose followed by maintenance dosing. Blocks IL-12 and IL-23 signaling.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.